Stockholders' Deficiency (Details Narrative) - USD ($)						1 Months Ended								9 Months Ended	12 Months Ended
	Jan. 09, 2020	Jan. 09, 2020	Dec. 19, 2019	Feb. 02, 2016	Feb. 02, 2016	Jan. 31, 2020	Dec. 31, 2019	Dec. 19, 2019	Oct. 31, 2019	Jul. 31, 2019	May 31, 2019	Mar. 31, 2018	Jul. 31, 2016	Dec. 31, 2015	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2015	Mar. 30, 2015
Common stock, shares authorized															125,000,000	125,000,000
Common stock, par value															$ 0.001	$ 0.001
Preferred stock, shares authorized															10,000,000	10,000,000
Preferred stock, par value															$ 0.001	$ 0.001
Shares exchangeable into equivalent common shares, issued															36,381,831	35,361,656
Shares exchangeable into equivalent common shares, outstanding															36,381,831	35,361,656
Common stock, shares issued															32,593,769	31,048,571
Common stock, shares outstanding															32,593,769	31,048,571
Exchangeable shares outstanding															3,788,062	4,313,085
Preferred stock, shares issued															1	1
Number of common shares issued, value															$ 28,566	$ 3,718,010
Accrued preferred stock dividends															257,927
Dividends paid															180,000
Issuance of shares for services, value															744,121	1,145,454
General and administrative and research and development expenses															10,259,903	7,342,739
Research and development expenses															$ 1,363,235	$ 1,309,191
Expected life																	3 years
Stock price												$ 1.032			$ 0.76	$ 0.588	$ 1.032
Stock based compensation															$ 2,408,713	$ 1,451,261
2015 Equity Incentive Plan [Member]
Number of common stock option exercise														3,390,503	164,590	164,590	164,590		3,390,503
Number of options authorized to issue																				3,000,000
Number of options vested
Number of options non-vested												137,500					137,500	137,500
Options exercise price												$ 0.0001		$ 0.0001			$ 0.0001	$ 0.0001	$ 0.0001
Number of options cancelled																	35,907
Fair value of options																			$ 2,257,953
Vesting description																			Options were exercised by those employees who met the vesting conditions; 50% of the grants either vest immediately or at the time of U.S. Food and Drug Administration (FDA) filing date and 50% will vest upon Liquidity Trigger. Liquidity Trigger means the day on which the board of directors resolve in favour of i) the Company is able to raise a certain level of financing; ii) a reverse takeover transaction that results in the Company being a reporting issuer, and iii) initial public offering that results in the Company being a reporting issuer.
Number of options granted														3,591,000
Number of options granted, exercise price														$ 0.0001
2016 Equity Incentive Plan [Member]
Number of common stock option exercise
Number of options authorized to issue				3,750,000	3,750,000
Options exercise price												$ 3.2306			$ 3.1069	$ 3.1436	$ 3.2306	$ 2.2031
Plan description					The maximum number of shares of stock that may be issued under the Plan pursuant to awards shall automatically and without any further Company or shareholder approval, increase on January 1 of each year for not more than 10 years from the Effective Date, so the number of shares that may be issued is an amount no greater than 15% of the Company's outstanding shares of stock and shares of stock underlying any outstanding exchangeable shares as of such January 1; provided further that no such increase shall be effective if it would violate any applicable law or stock exchange rule or regulation, or result in adverse tax consequences to the Company or any participant that would not otherwise result but for the increase.
Number of options granted												1,437,500			88,100	270,521	1,437,500	2,709,998
Number of options granted, exercise price															$ 0.7763	$ 1.8096	$ 5.1676	$ 2.2031
Stock based compensation																$ 1,451,261
2016 Equity Incentive Plan One [Member]
Number of options granted															88,100
Stock based compensation															$ 2,408,713
Intrinsic value of options															$ 0
Minimum [Member]
Expected life															2 years	2 years
Risk free rate															0.52%	2.27%	1.98%
Minimum [Member] | 2016 Equity Incentive Plan [Member]
Weighted average remaining contractual life												2 years 9 months 3 days				2 years 9 months 3 days
Minimum [Member] | 2016 Equity Incentive Plan One [Member]
Weighted average remaining contractual life															2 years 9 months 3 days
Maximum [Member]
Expected life															3 years	3 years
Risk free rate															2.81%	2.81%	2.39%
Maximum [Member] | 2016 Equity Incentive Plan [Member]
Weighted average remaining contractual life												9 years 6 months 3 days				9 years 6 months 3 days
Maximum [Member] | 2016 Equity Incentive Plan One [Member]
Weighted average remaining contractual life															9 years 6 months 3 days
Issuance of Common Shares [Member]
Number of common shares issued, shares																972,950
Number of common shares issued, value																$ 666,129
General and administrative and research and development expenses																$ 835,619
Employee Stock Options [Member]
Number of common stock option exercise																227,428
Promissory Notes [Member]
Conversion of stock, shares	1,830								1,830
Conversion of stock	$ 1,830,000
Warrant [Member]
Exchange ratio					All outstanding warrants at that time had been increased by a factor of 1.197.
Registered Offering [Member]
Number of common shares issued, shares										47,585	47,585					2,635,353
Proceeds from private offering										$ 28,565	$ 28,565					$ 3,718,010
Stock issuance cost																$ 80,000
Common Stock [Member]
Number of common shares issued, shares															47,585	2,635,353
Number of common shares issued, value															$ 48	$ 2,635
Proceeds from private offering															$ 28,565
Number of shares issued for services															972,590	641,329
Issuance of shares for services, value															$ 972	$ 641
General and administrative and research and development expenses																1,145,455
Warrants [Member]
Proceeds from warrants exercise																$ 50,835
Various Consultants [Member] | Common Stock [Member]
Number of common shares issued, shares																41,835
Various Consultants and Advisors [Member] | Issuance of Common Shares [Member]
Number of common shares issued, shares																174,590
Number of common shares issued, value																$ 169,490
Investors [Member] | Common Stock [Member]
Number of common shares issued, shares															525,023
Consultants, Advisors and Other Service Providers [Member] | Common Stock [Member]
Number of shares issued for services															178,750	62,085
Issuance of shares for services, value															$ 169,490	$ 91,498
Research and development expenses															$ 169,490
Consultants and Advisors [Member]
Proceeds from warrants exercise																$ 50,835
Number of warrants issued																62,838
Warrants exercise price																$ 0.81
Advisor and Consultant [Member]
Number of common stock compensation for services															1,021,430	849,601
Number of common stock compensation for services, value															$ 277,053	$ 467,411
Advisor and Consultant [Member] | Warrant [Member] | Minimum [Member]
Expected life															2 years	2 years
Risk free rate															0.22%	2.13%
Stock price															$ 0.974	$ 0.48
Expected volatility															114.30%	97.80%
Advisor and Consultant [Member] | Warrant [Member] | Maximum [Member]
Expected life															3 years	3 years
Risk free rate															1.71%	2.81%
Stock price															$ 0.52	$ 4.15
Expected volatility															132.20%	141.10%
Accredited Investors [Member] | Promissory Notes [Member]
General and administrative and research and development expenses															$ 184,637
Proceeds from issuance of warrants															$ 92,416
Officer [Member] | 2016 Equity Incentive Plan [Member]
Number of options granted													2,499,998
Number of options granted, exercise price													$ 2.20
Options vesting period													3 years
Two Employees [Member] | 2016 Equity Incentive Plan [Member]
Number of options granted													175,000
Number of options granted, exercise price													$ 2.24
Options vesting period													1 year
One Employee [Member] | 2016 Equity Incentive Plan [Member]
Number of options granted													35,000
Number of options granted, exercise price													$ 2.24
Options vesting period													2 years
Exchange Agreement [Member]
Percentage of common stock issued and outstanding				90.00%
Common stock exchange description				1.197 shares of its common stock in exchange for each common share
Number of common shares issued, shares				13,376,947
Exchange Agreement [Member] | 11% Secured Convertible Promissory Notes [Member]
Conversion description				The outstanding 11% secured convertible promissory notes of the Company were adjusted, in accordance with the adjustment provisions thereof, as and from closing, so as to permit the holders to convert (and in some circumstances permit the Company to force the conversion of) the convertible promissory notes into shares of the common stock of Biotricity at a 25% discount to purchase price per share in Biotricity's next offering.
Discount percentage for purchase price per shares				25.00%
Exchange Agreement [Member] | Warrant [Member]
Common stock exchange description				1.197 shares of the common stock of Biotricity for each Warrant, with an inverse adjustment to the exercise price of the Warrants to reflect the exchange ratio of approximately 1.197:1
Exchange ratio				1.197:1
Exchange Agreement [Member] | Advisor Warrant [Member]
Common stock exchange description				1.197 shares of the common stock of Biotricity for each Advisor Warrant, with an inverse adjustment to the exercise price of the Advisor Warrants to reflect the exchange ratio of approximately 1.197:1
Exchange ratio				1.197:1
Exchange Agreement [Member] | Options [Member]
Common stock exchange description				1.197 economically equivalent replacement options with an inverse adjustment to the exercise price of the replacement option to reflect the exchange ratio of approximately 1.197:1
Exchange ratio				1.197:1
Exchange Agreement [Member] | Sole Chief Executive Officer and Sole Officer [Member]
Common stock, shares outstanding				6,500,000	6,500,000
Exchange Agreement [Member] | Exchangeco [Member]
Common stock exchange description				1.197 Exchangeable Shares in the capital of Exchangeco in exchange for each common share of the Company held.
Number of exchangeable shares issued				9,123,031
Pre-Exchange Agreement [Member] | 2015 Equity Incentive Plan [Member]
Number of common stock option exercise																			2,832,500
Issuance of Employee Options [Member] | 2016 Equity Incentive Plan One [Member]
Stock price															$ 0.974
Expected volatility															132.20%
Weighted average remaining contractual life															10 years
Stock based compensation															$ 1,600,515
Issuance of Employee Options [Member] | Minimum [Member] | 2016 Equity Incentive Plan One [Member]
Risk free rate															0.46%
Issuance of Employee Options [Member] | Maximum [Member] | 2016 Equity Incentive Plan One [Member]
Risk free rate															0.75%
Series A Preferred Stock [Member]
Preferred stock, shares authorized							20,000								20,000
Preferred stock, par value															$ 0.001	$ 0.001
Preferred stock, shares issued	7,830	7,830	7,830			7,830	7,830	7,830							7,830
Number of common shares issued, shares		6,000	6,000			6,000	6,000
Series A Preferred Stock [Member] | Securities Purchase Agreement [Member]
Number of exchangeable shares issued								6,000
Proceeds from private offering								$ 6,000,000
Preferred stock, conversion method on issuance, description								The shares are convertible into common stock of the Company at a conversion price equal to the greater of $0.001 or a 15% discount to the 5-day volume weighted price at the time of conversion. The conversion rights commence 24 months after issuance, but conversion is limited to 5% of the aggregate purchase price of the holder on a monthly basis thereafter. Alternatively, the shares are convertible into common stock at a 15% discount to any qualified future common stock financing conducted by the Company. The Company may redeem the shares after 1 year for 110% of the purchase price plus accrued dividends. The preferred stock bears a dividend rate of 12% per annum